Yizhuo Zhao
Overview
Explore the profile of Yizhuo Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, et al.
Transl Lung Cancer Res
. 2022 Jun;
11(5):776-785.
PMID: 35693290
Background: Anlotinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with non-small cell lung cancer (NSCLC) in the...
12.
Mao X, Hu F, Peng J, Zhao Y, Gu A, Fang W, et al.
Ann Palliat Med
. 2022 Jun;
11(5):1605-1623.
PMID: 35672889
Comorbidity of lung cancer and chronic obstructive pulmonary disease (COPD) is very common. Surgical operation is the initial treatment of lung cancer. But surgery operation will aggravate the symptoms of...
13.
Zhao Y, Peng W, Abbas M, Shi M, Tang Y, Wang L, et al.
Invest New Drugs
. 2021 Aug;
40(1):209-214.
PMID: 34398354
Immunotherapy has been a revolutionary innovation in cancer therapy in recent years, but it is accompanied by various unique immune-related adverse events (irAEs). Among these irAEs, anaphylactic shock is very...
14.
Pan F, Lu A, Mao X, Chen Y, Zhao Y, Han B
J Multidiscip Healthc
. 2021 Aug;
14:2047-2052.
PMID: 34376986
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a valuable tool for diagnosing pulmonary disease due to its efficiency and safety. We retrospectively analyzed patients with mediastinal masses who underwent...
15.
Chen D, Xu J, Qiao R, Zhao Y, Chu T, Han B, et al.
J Oncol
. 2021 Mar;
2020:8811487.
PMID: 33643409
Some studies have revealed that specific genetic mutations could be associated with chemotherapy response or even survival in small-cell lung cancer (SCLC). Our retrospective study aimed to identify the correlation...
16.
Chang Q, Xu J, Qiang H, Teng J, Qian J, Lv M, et al.
Clin Lung Cancer
. 2020 Aug;
22(3):e395-e404.
PMID: 32747190
Introduction: Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to...
17.
Zhao Y
Int J Clin Exp Pathol
. 2020 Jan;
11(5):2597-2604.
PMID: 31938373
MicroRNAs (miRNA) play a crucial role in pathogenesis, progress, and prognosis of non-small-cell lung cancer (NSCLC). The purpose of this present study was to investigate the correlation of serum miR-141...
18.
Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H, et al.
J Ethnopharmacol
. 2019 Nov;
249:112404.
PMID: 31739105
Ethnopharmacological Relevance: Cardiac fibrosis is a common characteristic of many cardiac diseases. Our previous results showed that TRPM7 channel played an important role in the fibrosis process. MicroRNA-135a was reported...
19.
Chen D, Xu J, Zhao Y, Chu T, Zhong H, Han B, et al.
J Cancer Res Clin Oncol
. 2019 Nov;
146(2):401-406.
PMID: 31691871
Purpose: Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and tumor cell proliferation. The efficacy of anlotinib as a third-line or beyond therapy for SCLC was...
20.
Lu J, Zhong H, Wu J, Chu T, Zhang L, Li H, et al.
Adv Sci (Weinh)
. 2019 Oct;
6(19):1900721.
PMID: 31592412
Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non-small cell lung cancer (NSCLC) patients is still elusive. Here, tumor-specific target capture is used to profile the...